[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphomatoid-papulosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphomatoid-papulosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100330869","phase-2-dosing-of-brentuximab-vedotin-for-mycosis-fungoides-sezary-syndrome-patients-100330869",false,"NCT03587844","Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients","Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis","Inclusion Criteria:\n\nMycosis fungoides (MF) and Sezary Syndrome (SS)\n\n1. Pathologically confirmed mycosis fungoides\u002Fsezary syndrome at the enrolling institution, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher\n\n   ° CD30 negative mycosis fungoides patients are eligible.\n2. Age ≥ 18 years\n3. ECOG Performance Score ≤ 2\n4. For Cohort 1, patients who have not received brentuximab vedotin are eligible.\n5. For Cohort 2, patients who have previously had brentuximab vedotin for MF\u002FSS are eligible. Patients previously treated on Cohort 1 who were discontinued due to toxicity are not eligible for Cohort 2.\n6. Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.\n\n   ° See section 6.2 Subject Exclusion Criteria for guidelines regarding adjuvant and maintenance therapy for prior malignancy.\n7. Topical or systemic steroids (equivalent to ≤ 10 mg\u002Fday of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and\u002For unnecessary suffering, after discussion with PI.\n8. If HIV+, patient must be on stable anti-retroviral treatment for 12 weeks prior to C1D1, with CD4 count \\>200 within 7 days prior to C1D1.\n9. Females of childbearing potential must be on acceptable form of birth control per instutional standard.\n\nLymphomatoid papulosis (LyP)\n\n1. Pathologically confirmed lymphomatoid papulosis at the enrolling institution\n2. Requiring systemic treatment per investigator's discretion\n3. Age ≥ 18 years\n4. ECOG Performance Score ≤ 2\n5. Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.\n6. Topical or systemic steroids (equivalent to ≤ 10 mg\u002Fday of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and\u002For unnecessary suffering.\n7. If HIV+, patient must be on stable anti-retroviral treatment for 12 weeks prior to C1D1, with CD4 count \\>200 within 7 days prior to C1D1.\n8. Females of childbearing potential must be on acceptable form of birth control per institutional standard\n\nExclusion Criteria:\n\n1. Concurrent use of other systemic anti-cancer agents or treatments for mycosis fungoides\u002Fsezary syndrome, or lymphomatoid papulosis.\n2. Grade 2 or greater neuropathy\n3. Severe renal impairment (CrCL \\\u003C30 mL\u002Fmin)\n4. Moderate or severe hepatic impairment (Child-Pugh B or Child-Pugh C)\n\n   ° See Appendix E for Child Pugh Classification chart\n5. Women of reproductive potential† must have a negative Serum ß human chorionic gonadotropin (ß-HCG) pregnancy test within 1 week of C1D1. They should discuss contraception with treating provider.\n6. Previous use of brentuximab vedotin (for Cohort 1 ONLY)\n7. Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma).\n\n   * Patients with more than one type of lymphoma may be enrolled after discussion with the MSK Principal Investigator.\n   * Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator.\n8. For Cohort 2, patients who previously progressed on the standard 1.8mg\u002Fkg dose and schedule of brentuximab vedotin are ineligible.\n\n   * A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).","ALL","18 Years",{"count":19,"type":20},58,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.",[26,27,28],"Mycosis Fungoides","Lymphomatoid Papulosis","Sezary Syndrome",[30,31],"Brentuximab Vedotin","18-147","RECRUITING","2026-04-02",{"date":35,"type":36},"2026-04-03","ACTUAL",{"date":38,"type":36},"2018-07-03",{"date":40,"type":20},"2027-07",{"name":42,"class":43},"Memorial Sloan Kettering Cancer Center","OTHER",8,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100532054","long-term-outcomes-associated-with-juvenile-onset-mycosis-fungoides-and-lymphomatoid-papulosis-100532054","NCT06207812","Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis","Inclusion Criteria:\n\n-To be eligible, participants had to be diagnosed with jMF or lyp before age 20. In the case of participants below the age of 18, parents and not the children will be contacted for participation (children are exempt from participation as their parents may answer our study questions).\n\nExclusion Criteria:\n\n-Participants older than 20 years of age at diagnosis",{"count":52,"type":20},100,"OBSERVATIONAL","To follow up with all our participants with juvenile-onset mycosis fungoides, check on their status, and ask them or their parents about long term outcomes associated with their condition.",[27,26],"2026-01-23",{"date":58,"type":36},"2026-01-26",{"date":60,"type":36},"2024-01-19",{"date":62,"type":20},"2028-01-12",{"name":64,"class":43},"M.D. Anderson Cancer Center",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":65},"100273556","tissue-repository-ctcl-collection-protocol-100273556","NCT02840747","Tissue Repository: CTCL Collection Protocol","A Tissue Repository for the Collection of Samples From Patients With Cutaneous T Cell Lymphoma and Healthy Volunteers","Inclusion Criteria:\n\n* Patients with CTCL or Lymphomatoid Papulosis (LYP): a clinical or histologic diagnosis of a) newly diagnosed, b) progressive, or c) relapsed CTCL or LYP who are initiating or changing therapy.\n* Patients with Sézary Syndrome (SS) or stage IV B CTCL as defined by blood involvement on flow cytometry or morphology: (1) ≥1000\u002FμL Sézary cells by morphology; (2) Cluster of differentiation 4 (CD4)\u002Fcluster of differentiation 8 (CD8) ratio ≥10; (3) CD4+cluster of differentiation 7 (CD7)- cells ≥40 percent; (4) or CD4+cluster of differentiation 26 (CD26)- cells ≥30 percent.\n* Ability to understand and willing to sign a willing informed consent document.\n* Age ≥ 18 years.\n\nInclusion Criteria for Age and Sex Matched Controls:\n\n* Matched for sex, and age +\u002F- 10 years.\n* Ability to sign informed consent document.\n* Patients with or without benign inflammatory skin conditions including, but not limited to, eczema, psoriasis, or dermatitis or Patients without skin conditions requiring treatment with systemic immunosuppressive, biologic, or chemotherapeutic agents.\n\nExclusion Criteria:\n\n* Patients with a history of previous lymphoma other than CTCL or SS or LYP.\n* Medical illnesses with potential suppressive or activating impact on immune and bowel function as judged by the investigator.\n* Current, viable pregnancy.\n* Anemia with a documented hemoglobin laboratory value of \\\u003C7.5 g\u002Fdl within the past 6 months.\n\nExclusion Criteria for Age and Sex Matched Controls:\n\n* Previous history of CTCL, SS, LYP, or any lymphoma.\n* Previous history of Human Immunodeficiency Virus (HIV) infection.\n* Anemia with a documented hemoglobin laboratory value of \\\u003C7.5 g\u002Fdl within the past 6 months.",true,{"count":75,"type":20},400,"This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL). The purpose of this study is to establish a protocol for the collection and storage of tissue samples from patients with CTCL for future research studies. Collection and storage of tissue samples from control patients will also be carried out.",[78,27,79],"Lymphoma, T-Cell, Cutaneous","Sézary Syndrome",[27,79,81],"T-Cell Lymphoma","2025-11-03",{"date":84,"type":36},"2025-11-04",{"date":86,"type":4},"2016-07",{"date":88,"type":20},"2026-10",{"name":90,"class":43},"Columbia University"]